|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-148.69|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Galapagos popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron and Sanofi.
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Gilead Sciences, Inc. (NASDAQ:GILD) might as well have quashed rumors making waves claiming it is planning to acquire Belgium-based Galapagos NV (ADR) (NASDAQ:GLPG). The drug maker is paying a $50 million milestone payment for the development of Crohn’s drug filgotinib, and that appears to be its main play for the moment. Filgotinib Phase 3 Trial […]
Galapagos NV (ADR) (NASDAQ:GLPG) just updated the markets as to the status of a couple of its lead development programs, and while the company hasn’t really moved on the update, there’s plenty of potential for volatility going forward as the content of the releases plays out. Here’s what’s important. The company is a biotech based […]